Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06034821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

Study acronym: REaKT-SD
StatusEnrolling by Invitation
PhasePhase 4
Started2023-10-01
View on ClinicalTrials.gov ↗

Amendment history

2025-12-08
Study Status, Sponsor/Collaborators, Eligibility, Contacts/Locations v6
Study sites11→10
Eligibility criteriarevised
[...] less of medical lethality, if intent to die was indicated). * Continue to express suicidal ideation since referral as evidenced by Scale for Suicidal Ideation (SSI) ≥6)** Meet the following criteria on symptom rating scales at screening: Hamilton Depression Scale (HAM-D 17) >15 and Montreal Cognitive Assessment (MoCA) of ≥23(to rule out bas [...]
Collaborators9 to 11 entries
BaylorUT CollegeHealth Mclean ofHospital Massachusetts MedicineGeneral Hospital University of ArizonaUtah WashingtonUC UniversitySan School of MedicineFrancisco
2025-09-15
Study Status v5
Primary completion date2030-01-01→2030-10-01
Completion date2030-03-01→2030-12-01
2024-08-26
Study Status, Eligibility, Contacts/Locations v4
Study sites9→11
Eligibility criteria+157 characters
Inclusion Criteria: ReferredConsidered by a clinician as appropriate for referral to ECTtreatment service as a candidateservices for ECTrapid treatmentreversal asof assessedacute bysuicidal treating cliniciandepression. Males/femalesAdults 18 - 90 years of age. Meet DSM-5 criteria for Major Depress [...] International Neuropsychiatric Interview (MINI PLUS 5.0.0). ExpressingAcute suicidal intentideation or behavior (thinking or behavior suggesting harming or hurting oneself with intentknowledge that death may result) or attempt (any intentional, non-fat [...] teria for KET treatment such as: Pregnant or brea [...]
2024-06-27
Study Status v3
Re-verified, no change to tracked fields
2024-01-18
Not Yet Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Enrolling by Invitation
Study sitescontacts updated at 9 of 9 sites
2023-09-28
Study Identification, Study Status, Contacts/Locations v1
Study sites0→9
2023-09-11
Original filing
This study is a randomized open-label single-blind non-inferiority comparative effectiveness study of ECT vs. KET for the treatment of Acute Suicidal Depression (ASD).
Trial Details
NCT Number NCT06034821
Lead Sponsor Brigham and Women's Hospital
Collaborators: Johns Hopkins University, University of Pittsburgh, The Cleveland Clinic, Icahn School of Medicine at Mount Sinai, University of Toronto, The University of Texas Health Science Center, Houston, UT Health, Mclean Hospital, Massachusetts General Hospital, University of Utah, UC San Francisco
Conditions Acute Suicidal Depression (ASD)
Enrollment 1,500 participants
Start Date 2023-10-01
Primary Completion 2030-10-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-15